Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial

M. Tabberer (Middlesex, United Kingdom), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Middlesex, United Kingdom), G. Criner (Philadelphia, United States of America), P. Lange (Copenhagen, Denmark), M. Han (Ann Arbor, United States of America), F. Martinez (New York, United States of America), D. Lipson (King of Prussia, United States of America)

Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Tabberer (Middlesex, United Kingdom), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Middlesex, United Kingdom), G. Criner (Philadelphia, United States of America), P. Lange (Copenhagen, Denmark), M. Han (Ann Arbor, United States of America), F. Martinez (New York, United States of America), D. Lipson (King of Prussia, United States of America). Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial. 1996

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: